FDA Continues Efforts to Support Innovation in Medical Device Sterilization

The following statement is attributed to Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health The sterilization of medical devices is a vital process for helping to prevent serious infections. The U.S. Food and Drug Administration...

Surfacide Earns High Marks in KLAS Research Report

In a newly released report from KLAS Research, a health care research firm, Surfacide UV Technology has received all “A” ratings for its Helios UV-C System. The report’s performance insights include product satisfaction, customer support, value, loyalty, culture and...

Wolters Kluwer Supports Floating Hospital

Wolters Kluwer, Health has donated three market-leading clinical decision support (CDS) tools including UpToDate, Lexicomp and Lippincott Procedures to Mercy Ships, a global humanitarian organization that operates two floating hospitals serving underprivileged...

Miniaturized Robotic-Assisted Surgery Device Headed into Space

Virtual Incision Corporation, a medical device company working on a miniaturized robotic-assisted surgery (RAS) platform, has announced that its MIRA Platform will test its skills in space on a 2024 technology demonstration mission aboard the International Space...

New Data on OviTex in Hernia Repair Applications

TELA Bio, Inc., a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, has announced details of the clinical research presented last week at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting in Las Vegas, Nevada.

Two poster presentations revealed new data, while a third video presentation demonstrated a novel surgical technique that leverages the unique properties of OviTex® Reinforced Tissue Matrix.

Robotic Assisted ReBAR of 111 Inguinal Hernias, presented by Dr. Cory Banaschak, DO and Dr. Paul Szotek, MD, MBA, FACS, Medical Director of the Indiana Hernia Center, revealed a 2.7% recurrence rate, a 1.8% surgical site occurrence rate, and no infections in patients with at least one year of follow-up. The authors concluded that robotic transabdominal preperitoneal (rTAPP) inguinal hernia repair with OviTex presents a viable and more natural repair alternative in minimally invasive surgery, an approach typically reserved for permanent synthetic meshes. Dr. Szotek stated, “The Reinforced Biologic Augmented Repair, or the ReBAR technique, applies sound hernia surgery principles while leveraging the benefits of a reinforced biologic material with a low synthetic foreign body burden. Our initial goals in adopting OviTex were to lower recurrences while decreasing the amount of synthetic foreign body implanted. That’s what patients are increasingly looking for, and it makes a lot of clinical sense if you can achieve it. With over five years of experience utilizing the ReBAR technique with OviTex, it appears that we are on the way to achieving these goals.”

Additional data on hernia repairs performed by Drs. Szotek and Banaschak employing the ReBAR technique was recently highlighted in an article entitled, Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR) published in the Journal of Clinical and Medical Research. In this prospective study of 619 implants using the ReBAR technique for a variety of open and minimally invasive inguinal and abdominal hernia repairs the authors reported an overall recurrence rate of 1.3%.

Use of Ovine Reinforced Tissue Matrix in Bridged Incisional Hernia Repair, presented by Dr. DeNoto III, MD, FACS, Director of General Surgery at St. Francis Hospital in New York, analyzed recurrence rates in the treatment of abdominal hernias that require reinforcement in the absence of a primary repair. “These are some of the most complex and challenging patients to reduce the potential of a future hernia recurrence,” said Dr. DeNoto. In this series, patients with bridged repairs using OviTex had a 14% recurrence rate. “To put the results of our study in perspective, at similar time points we have seen recurrence rates more than double when repaired with human or porcine mesh products. This is a major reason why patients presenting with bridged repairs are so difficult to treat and why an effective reinforcement option is much needed.”

For more information on the SAGES poster presentations, visit



Submit a Comment

Your email address will not be published.